Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Wills Eye
Study ID
NCT00853073
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
  • balanced salt solution — OTHER
    0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure

Study Details

The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.

Key Dates

First listed
Feb 27, 2009
Start date
Feb 28, 2009
Status verified
Jun 2018
Primary completion
Jan 31, 2012
Completion
Jan 31, 2012

Study Design

Enrollment
63 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Bevacizumab
    subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
  • Placebo Comparator: balanced salt solution
    patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.

Primary Outcome Measure

Intraocular Pressure (IOP) [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Wills Eye Institute, Glaucoma ServicePhiladelphiaPennsylvania19107-

Find similar trials in Philadelphia, PA

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Wills Eye Institute, Glaucoma Service· Philadelphia, PA

Related Studies